Drug developers looking to Xolair's example in a changing asthma market, study says

10 November 2016

Biologics and monoclonal antibodies (MAbs) will become a bigger presence within the asthma therapeutics market, according to a new report from business intelligence firm GBI Research.

The report notes that small molecules currently account for 98% of available products in this therapeutic space, but highlights that the asthma pipeline consists of 12% MAbs and 17% non-MAb biologics.

One of the few currently-marketed MAb asthma therapeutics is Xolair (omalizumab) from Roche (ROG: SIX) subsidiary Genentech, which reached blockbuster status in 2014. It is approved for adults and adolescents aged 12 and over, with moderate-to-severe allergic asthma and symptoms not adequately controlled with inhaled corticosteroids.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK